<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83986">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915849</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066A2201</org_study_id>
    <nct_id>NCT01915849</nct_id>
  </id_info>
  <brief_title>Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Crossover Trial to Assess the Effect of Orally Administered LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the effect of LIK066 on intestinal glucose absorption
      immediately after a single dose (immediate effect) and 6 hours following the dose (after
      multiple daily doses; sustained effect) in patients with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Area under the postprandial curve (AUC) for rate of appearance (Ra) of exogenous glucose</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effect of single dose (day 1) and multiple doses (day 4) will be assessed</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LIK066 Dose 1/Placebo/LIK066 Dose 2/LIK066 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 Dose 2 treatment once daily (q.d.) for 4 days. Period 4- LIK066 Dose 3 treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 Dose 2/LIK066 Dose 1/LIK066 Dose 3/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- LIK066 Dose 2 treatment once daily (q.d.) for 4 days. Period 2- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. Period 3 - LIK066 Dose 3 treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days . 14 days washout periods between treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 Dose 3/ LIK066 Dose 2/Placebo/LIK066 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- LIK066 Dose 3 treatment once daily (q.d.) for 4 days. Period 2- LIK066 Dose 2 treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/LIK066 Dose 3/LIK066 Dose 1/LIK066 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 Dose 3 treatment once daily (q.d.) for 4 days. Period 3- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. Period 4- LIK066 Dose 2 treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <arm_group_label>LIK066 Dose 1/Placebo/LIK066 Dose 2/LIK066 Dose 3</arm_group_label>
    <arm_group_label>LIK066 Dose 2/LIK066 Dose 1/LIK066 Dose 3/Placebo</arm_group_label>
    <arm_group_label>LIK066 Dose 3/ LIK066 Dose 2/Placebo/LIK066 Dose 1</arm_group_label>
    <arm_group_label>Placebo/LIK066 Dose 3/LIK066 Dose 1/LIK066 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>LIK066 Dose 1/Placebo/LIK066 Dose 2/LIK066 Dose 3</arm_group_label>
    <arm_group_label>LIK066 Dose 2/LIK066 Dose 1/LIK066 Dose 3/Placebo</arm_group_label>
    <arm_group_label>LIK066 Dose 3/ LIK066 Dose 2/Placebo/LIK066 Dose 1</arm_group_label>
    <arm_group_label>Placebo/LIK066 Dose 3/LIK066 Dose 1/LIK066 Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, age 18-65 years, must have been diagnosed with T2DM at least 6 months prior
             to screening with HbA1c 6.5 to 10.0%, inclusive, at screening.

          -  Fasting plasma glucose â‰¤250mg/dL at screening.

          -  If treated with metformin, patients must be on a stable dose for 12 weeks prior to
             randomization and maintain the dose until the end of the study.

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus.

          -  Patients with history of acute diabetic complications within the 6 months prior to
             screening.

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential unless they are using effective methods of
             contraception during dosing of study treatment.

          -  Patients with signs or symptoms of significant diabetic complications.

          -  Patients treated with certain blood pressure or lipid lowering medications unless
             patients have been on stable doses for the 12 weeks prior to dosing.

          -  History of drug or alcohol abuse within the 12 months prior to dosing.

          -  Any surgical or medical condition, acute or unstable chronic disease which may, based
             on the investigator's opinion, jeopardize the patient in case of participation in the
             study.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>August 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
